NCT03147404View on ClinicalTrials.gov

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions

Neuroendocrine Carcinoma, Grade 3

Interventions

DRUG

Avelumab

Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors

collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Samsung Medical Center

OTHER

NCT03147404 - Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes | Biotech Hunter | Biotech Hunter